Literature DB >> 3200833

Molecular analysis of the 60-kDa human Ro ribonucleoprotein.

S L Deutscher1, J B Harley, J D Keene.   

Abstract

Ro, or Sjogren syndrome type A (SS-A), antigen is the most prevalent of the human systemic autoimmune specificities and exists as an inabundant ribonucleoprotein complex (RNP) composed of a 60,649-Da protein, as defined here by cDNA cloning, and the human Y RNAs. The recombinant 60-kDa Ro protein and human Y1 RNA were reconstituted in vitro, and the binding was enhanced by divalent cations. A region of the Ro amino acid sequence revealed a resemblance to the RNP consensus motif found in most RNA-binding proteins. In addition, Ro contained a potential "zinc-binding finger" motif that was distinct from the RNP consensus region and that may participate in the interaction with human Y RNAs or with other proteins. The recombinant Ro fusion protein also proved useful for the detection of autoantibodies in the sera of patients with autoimmune disorders. Possible functions of the Ro RNPs and their relationship to RNA polymerase III transcription are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3200833      PMCID: PMC282776          DOI: 10.1073/pnas.85.24.9479

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; N Talal; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

2.  Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis.

Authors:  D W Cleveland; S G Fischer; M W Kirschner; U K Laemmli
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

3.  Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythmatosus.

Authors:  G Clark; M Reichlin; T B Tomasi
Journal:  J Immunol       Date:  1969-01       Impact factor: 5.422

4.  Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing.

Authors:  F Sanger; A R Coulson; B G Barrell; A J Smith; B A Roe
Journal:  J Mol Biol       Date:  1980-10-25       Impact factor: 5.469

5.  Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins.

Authors:  J Garnier; D J Osguthorpe; B Robson
Journal:  J Mol Biol       Date:  1978-03-25       Impact factor: 5.469

6.  Sequencing end-labeled DNA with base-specific chemical cleavages.

Authors:  A M Maxam; W Gilbert
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

7.  Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus.

Authors:  M R Lerner; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

8.  Antibodies to cellular antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; E M Tan
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

9.  Precursor molecules of both human 5S ribosomal RNA and transfer RNAs are bound by a cellular protein reactive with anti-La lupus antibodies.

Authors:  J Rinke; J A Steitz
Journal:  Cell       Date:  1982-05       Impact factor: 41.582

10.  Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells.

Authors:  J P Hendrick; S L Wolin; J Rinke; M R Lerner; J A Steitz
Journal:  Mol Cell Biol       Date:  1981-12       Impact factor: 4.272

View more
  77 in total

1.  Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjögren's syndrome and systemic lupus erythematosus.

Authors:  N Pourmand; M Wahren-Herlenius; I Gunnarsson; E Svenungsson; B Löfström; Y Ioannou; D A Isenberg; C G Magnusson
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  IgG antibodies from patients with primary Sjögren's syndrome and systemic lupus erythematosus recognize different epitopes in 60-kD SSA/Ro protein.

Authors:  S Barakat; O Meyer; F Torterotot; P Youinou; J P Briand; M F Kahn; S Muller
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

Review 3.  B-cell epitopes of La and Ro autoantigens.

Authors:  S Whittingham
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

Review 4.  Autoantibodies against small cytoplasmic ribonucleoproteins: the anti-Ro/SS-A and anti-La/SS-B autoimmune response. A review of autoantibody detection, autoantigen composition, autoantibody-disease associations and possible etiologic mechanisms.

Authors:  J F Meilof
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 5.  Anti-Ro (SSA)/La (SSB) antibodies and Sjögren's syndrome.

Authors:  H M Moutsopoulos; L V Zerva
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 6.  Antinuclear antibody determination methods.

Authors:  D G Williams; P J Charles; M Field; S M Chua; R N Maini
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 7.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

8.  Calreticulin binds preferentially with B cell linear epitopes of Ro60 kD autoantigen, enhancing recognition by anti-Ro60 kD autoantibodies.

Authors:  E V Staikou; J G Routsias; A A Makri; A Terzoglou; M Sakarellos-Daitsiotis; C Sakarellos; G Panayotou; H M Moutsopoulos; A G Tzioufas
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

9.  Xenopus Ro ribonucleoproteins: members of an evolutionarily conserved class of cytoplasmic ribonucleoproteins.

Authors:  C A O'Brien; K Margelot; S L Wolin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

10.  Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases.

Authors:  J G Routsias; A G Tzioufas; M Sakarellos-Daitsiotis; C Sakarellos; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.